[go: up one dir, main page]

CL2009000905A1 - Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad. - Google Patents

Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad.

Info

Publication number
CL2009000905A1
CL2009000905A1 CL2009000905A CL2009000905A CL2009000905A1 CL 2009000905 A1 CL2009000905 A1 CL 2009000905A1 CL 2009000905 A CL2009000905 A CL 2009000905A CL 2009000905 A CL2009000905 A CL 2009000905A CL 2009000905 A1 CL2009000905 A1 CL 2009000905A1
Authority
CL
Chile
Prior art keywords
anxiety
treat
edible composition
related disorders
bifidobacterium longum
Prior art date
Application number
CL2009000905A
Other languages
English (en)
Inventor
Gabriela Bergonzelli
Kurt Ornstein
Christine Cherbut
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39687058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000905(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2009000905A1 publication Critical patent/CL2009000905A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Husbandry (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Physiology (AREA)

Abstract

Composición comestible que comprende bifidobacterium longumatcc baa-999; y su uso para tratar o evitar enfermedades neurodegenerativas.
CL2009000905A 2008-04-15 2009-04-15 Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad. CL2009000905A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08154550A EP2110028A1 (en) 2008-04-15 2008-04-15 Bifidobacterium longum and hippocampal BDNF expression

Publications (1)

Publication Number Publication Date
CL2009000905A1 true CL2009000905A1 (es) 2010-08-20

Family

ID=39687058

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000905A CL2009000905A1 (es) 2008-04-15 2009-04-15 Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad.

Country Status (9)

Country Link
US (1) US8343482B2 (es)
EP (5) EP2110028A1 (es)
JP (3) JP5964586B2 (es)
CN (1) CN102065710B (es)
CL (1) CL2009000905A1 (es)
DK (1) DK3072398T3 (es)
ES (2) ES2674276T3 (es)
TW (1) TW200948372A (es)
WO (1) WO2009127566A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
EP2438821B1 (en) 2008-11-03 2020-01-15 Société des Produits Nestlé S.A. A nutritional composition comprising probiotics and improving sleep patterns
DK2289527T3 (en) 2009-08-25 2018-04-23 Nestec Sa BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISEASES
ES2595444T3 (es) * 2009-11-11 2016-12-30 Alimentary Health Limited Cepa de Bifidobacterium probiótica
JP2013119546A (ja) * 2011-12-09 2013-06-17 Meiji Co Ltd 不安及び／又は多動性の改善剤
BR112014021388A2 (pt) 2012-02-29 2017-07-18 Ethicon Endo Surgery Inc composições de microbiota e métodos rela-cionados às mesmas
CN104046573B (zh) * 2013-03-11 2017-01-18 中国农业大学 长双歧杆菌及其应用以及功能食品组合物及其制备方法
GB201305708D0 (en) * 2013-03-28 2013-05-15 Clasado Inc Novel use
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
CN104413334A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
CN103789268B (zh) * 2014-02-21 2016-04-27 刘洛贤 一种分离培养海马神经细胞的方法及其专用培养液
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
JP6234331B2 (ja) * 2014-06-13 2017-11-22 森永乳業株式会社 統合失調症治療剤
JP6382027B2 (ja) * 2014-08-26 2018-08-29 サンスター株式会社 ビフィズス菌及びアブラナ科野菜を含有する経口組成物
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
MX382895B (es) 2015-06-11 2025-03-13 Soc Des Produits Nestle S A Star Suplemento dietético.
CA2994345A1 (en) * 2015-08-31 2017-03-09 Nestec S.A. Methods and compositions using bifidobacterium longum to treat or prevent depressive symptoms
EP3344269A1 (en) * 2015-08-31 2018-07-11 Nestec S.A. Methods and compositions using bifidobacterium longum to optimize breastfeeding
HK1263322A1 (zh) * 2015-08-31 2020-04-17 Société des Produits Nestlé S.A. 使用长双歧杆菌调节情绪反应性并治疗或预防亚临床心境紊乱的方法和组合物
FR3046908B1 (fr) * 2016-01-21 2019-06-21 Domes Pharma Complement alimentaire pour utilisation dans la lutte contre le stress et l'anxiete chez les animaux de compagnie
JPWO2017130859A1 (ja) * 2016-01-28 2018-11-15 森永乳業株式会社 神経細胞死抑制剤
WO2017155861A1 (en) * 2016-03-10 2017-09-14 Peachstate Health Management Llc Dba Aeon Clinical Laboratories Methods of treating substance abuse related diseases or disorders
JP6353478B2 (ja) * 2016-03-28 2018-07-04 日清食品ホールディングス株式会社 セロトニン分泌促進能力を有するビフィズス菌
CN109069555B (zh) 2016-04-13 2022-07-26 株式会社明治 面向新生儿的用于改善脑功能的组合物
KR102844378B1 (ko) 2016-05-31 2025-08-07 모리나가 뉴교 가부시키가이샤 뇌기능 개선제
EP3478305A1 (en) * 2016-07-01 2019-05-08 Nestec S.A. Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal
IT201600084470A1 (it) 2016-08-10 2018-02-10 Probiotical Spa Composizione per uso nel trattamento del disturbo depressivo maggiore
EP3618843A1 (en) * 2017-05-05 2020-03-11 Société des Produits Nestlé S.A. Treatment of infant colic
CA3066561C (en) * 2017-06-14 2022-07-19 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus megasphera and uses thereof
PT3664894T (pt) 2017-08-11 2021-12-17 Biocodex Saccharomyces boulardii para o tratamento de perturbações do humor
AU2018326705A1 (en) 2017-08-30 2020-03-05 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
WO2019098810A2 (ko) * 2017-11-20 2019-05-23 경희대학교 산학협력단 신규 유산균 및 이의 용도
KR102250597B1 (ko) 2017-11-20 2021-05-11 경희대학교 산학협력단 신규 유산균 및 이의 용도
KR102712414B1 (ko) 2017-12-19 2024-09-30 프로바이오티컬 에스.피.에이. 수면 장애 및 기분 장애를 치료 및/또는 개선하기 위한 조성물
KR102230571B1 (ko) * 2018-03-22 2021-03-22 한국식품연구원 비형광성 최종당화산물 억제용 조성물 및 이의 용도
WO2020018949A2 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
WO2020037533A1 (zh) * 2018-08-22 2020-02-27 江南大学 长双歧杆菌婴儿亚种ccfm687、其发酵食品及其应用
JP2020037526A (ja) * 2018-09-04 2020-03-12 株式会社明治 脳機能を改善するための組成物
CN109349645A (zh) * 2018-10-30 2019-02-19 广州普维君健药业有限公司 益生菌组合物、保健食品及其制备方法和应用
CN109364097B (zh) * 2018-11-05 2021-06-29 福州大学 瓜尔豆胶在制备抗抑郁症药物中的应用
CN111202754A (zh) * 2019-03-11 2020-05-29 江苏佰澳达生物科技有限公司 一种预防和改善老年痴呆症的益生菌组合物及其应用
CN111297915B (zh) * 2019-04-12 2021-11-23 首都医科大学附属北京友谊医院 治疗帕金森病快速眼动期睡眠行为障碍的益生菌组合物、制剂及用途
JP7503899B2 (ja) * 2019-07-24 2024-06-21 雪印メグミルク株式会社 記憶・学習能維持および／または向上用組成物及び組成物を含む食品、医薬品、飼料
JP7149427B2 (ja) 2019-08-08 2022-10-06 森永乳業株式会社 学童期の記憶能向上のための乳幼児用組成物
CN110787190B (zh) * 2019-12-17 2020-06-16 杨波 一种具有抗衰老作用的复合益生菌组合物及其制法和应用
EP4091673A4 (en) * 2020-01-17 2024-01-31 Morinaga Milk Industry Co., Ltd. ANTI-AGING COMPOSITION
CN111560331B (zh) * 2020-05-15 2021-11-09 诺佰克（武汉）生物科技有限公司 一株副干酪乳杆菌及其应用
KR102396476B1 (ko) * 2020-10-29 2022-05-10 엠테라파마 주식회사 신규한 비피도박테리움 롱검 z1 균주 및 이의 용도
CN114098084A (zh) * 2021-04-13 2022-03-01 中国人民解放军军事科学院军事医学研究院 一种缓解长期低剂量辐射暴露所致认知损伤的益生菌组合物及其应用
CN113322213B (zh) * 2021-07-09 2022-05-13 吉林大学 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用
CN114634900B (zh) * 2022-05-18 2022-08-19 鲁东大学 一株屎肠球菌ld-nxy01及其在海马养殖中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
JP2826808B2 (ja) * 1995-07-14 1998-11-18 カルピス株式会社 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品
JP4044630B2 (ja) * 1996-05-16 2008-02-06 雪印乳業株式会社 脳機能改善剤
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US6444203B2 (en) * 1999-12-20 2002-09-03 Compagnie Gervais Danone Administering bacteria to improve sleep
JP2003252771A (ja) * 2002-03-04 2003-09-10 Snow Brand Milk Prod Co Ltd 加齢に伴う代謝異常疾患の予防・改善・治療剤
JP2004262773A (ja) * 2003-02-17 2004-09-24 Ryoshoku Kenkyukai 免疫機能改善を目的としたビフィズス菌製剤
US20040265279A1 (en) 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
JP2007508233A (ja) * 2003-10-08 2007-04-05 雅美 森山 抗ウイルス剤
PT1940248E (pt) * 2005-10-05 2010-01-26 Nestec Sa Utilização de uma composição nutricional para promoção do crescimento acelerado
JP5537809B2 (ja) * 2005-12-15 2014-07-02 ネステク ソシエテ アノニム 脳機能を維持するための組成物及び方法
JP2007169200A (ja) * 2005-12-21 2007-07-05 Morinaga Milk Ind Co Ltd インフルエンザ感染予防のための医薬及び飲食品
MX2008010422A (es) * 2006-02-15 2008-10-27 Nestec Sa Uso de bifidobacterium longum para la prevencion y tratamiento de inflamacion.
JP2008081434A (ja) * 2006-09-27 2008-04-10 Univ Of Miyazaki 気分改善剤
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
WO2010008272A1 (en) 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
DK2289527T3 (en) 2009-08-25 2018-04-23 Nestec Sa BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISEASES

Also Published As

Publication number Publication date
JP6554730B2 (ja) 2019-08-07
JP2011517568A (ja) 2011-06-16
DK3072398T3 (en) 2018-08-27
US20110280837A1 (en) 2011-11-17
EP2110028A1 (en) 2009-10-21
EP3398446B1 (en) 2020-02-19
US8343482B2 (en) 2013-01-01
ES2674276T3 (es) 2018-06-28
EP3072398A1 (en) 2016-09-28
ES2780389T3 (es) 2020-08-25
JP2017160200A (ja) 2017-09-14
JP6114247B2 (ja) 2017-04-12
EP3398446A1 (en) 2018-11-07
EP3673744A1 (en) 2020-07-01
JP2015077133A (ja) 2015-04-23
JP5964586B2 (ja) 2016-08-03
WO2009127566A1 (en) 2009-10-22
EP3072398B1 (en) 2018-05-23
EP2291089A1 (en) 2011-03-09
TW200948372A (en) 2009-12-01
CN102065710A (zh) 2011-05-18
CN102065710B (zh) 2018-04-13

Similar Documents

Publication Publication Date Title
CL2009000905A1 (es) Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad.
CL2012000487A1 (es) Composicion que comprende bifidobacterium longum baa-999 para tratar y/o prevenir trastornos gi funcionales.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
CL2011000891A1 (es) Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales.
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CO6551686A2 (es) Inmunoglobinas con dominio variable dual y usos de las mismas
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
HN2011002037A (es) Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
CL2011002818A1 (es) Composicion de leche para el crecimiento que comprende microorganismos probioticos; uso de dicha composicion para preparar medicamento util para prevenir o tratar trastornos inflamatorios.
ECSP13012379A (es) Pirimidinas y triazinas condensadas y su uso
ECSP10010295A (es) Formulacion de anticuerpo
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
ECSP10010216A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
CL2011002835A1 (es) Compuestos derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para tratar dolores agudos o cronicos de tipos neurogeno, asociados a enfermedades inflamatorias, entre otros.
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
BRPI0820465A2 (pt) Conjunto picador autocontido para reduzir e classsificar meterial
MX2013007735A (es) Fibra y probioticos para reducir sintomas intestinales relacionados con estres cronico.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso